Dirk Blom

Statistics

Publications

Citations

16.4K

H-Index

Active since

2002

Affiliations

University of Cape Town(Current)

University of the Witwatersrand

Amgen (United States)

Amsterdam UMC Location University of Amsterdam

Universidade de São Paulo

Dirk Blom is an author at University of Cape Town specializing in pharmacology, lipid-lowering therapy, and low-density lipoprotein cholesterol lowering.

ORCID

Publications per year

2002–2025

Publications

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Raúl D. Santos, Dirk Blom et al. · The Lancet · 2010 · 906 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Marina Cuchel, Emma A. Meagher, Hendrik du Toit Theron et al. · The Lancet · 2012 · 740 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Narimon Honarpour, Dirk Blom et al. · The Lancet · 2014 · 727 citations

Life Sciences, Genetics, Pharmacology +14

1–5 of 81